News

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) — which was set for May 14–15 in…

FDA Names AMP945, Potential IPF Treatment, an Orphan Drug

The U.S. Food and Drug Administration (FDA) has designated AMP945, Amplia Therapeutics’ investigational anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF), an orphan drug, supporting its development, the company announced. Its decision came about one month after AMP945 also received orphan drug status as a potential pancreatic cancer…

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) — which was set for May 14–15 in…

Repeat Hospitalizations in IPF Patients Linked to Poor Survival in Study

Repeat hospitalizations for respiratory problems in people with chronic idiopathic interstitial pneumonia (c-IIP) — a group of chronic lung diseases that also include idiopathic pulmonary fibrosis (IPF) — are associated with poor long-term survival, a study reported. The study, “Characteristics of patients with chronic idiopathic interstitial…

Algernon Gets Nod to Launch Phase 2 IPF Trial of NP-120 in Australia

Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. Royal Brisbane and Women’s Hospital‘s Human Research Ethics Committee has approved two sites — the Cairns…